Bergen, Norway, 12 November 2025: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), publishes its Q3 2025 financial report and operational update.
Highlights:
* Secured NOK 80 million, supporting next development and regulatory
milestones
* Finalized product design and production setup, positioning for near-term
veterinary market entry
* Entered final regulatory review phase for first-in-human clinical approval
Diabetes affects over 600 million people worldwide, creating growing demand
for reliable and driving rapid glucose monitoring. Lifecare is developing a
fully implantable, miniaturized Continuous Glucose Monitoring (CGM) system
designed for long-term accuracy, ease of use, and cost efficiency, advancing
toward clinical validation and future commercialization.
Q3 focused on securing financing to ensure sufficient working capital and
continued product development. While operations largely stayed on plan,
liquidity constraints required a temporary slowdown in production workstreams,
delaying completion of devices needed for the longevity trial LFC-SEN-002.
At the end of October, the Board announced a partially underwritten rights
issue expected to raise NOK 80--100 million in January 2026, to be followed by
two warrant exercise periods. Bridge financing will ensure operations until
completion of the rights issue. The planned financing will enable continued
product development, support the veterinary market launch, and advance CE-mark
preparations for the human market. For further details regarding the
financing, please refer to Note 9.
Early results from the longevity trial in dogs confirm excellent
biocompatibility, safety, and reliable end-to-end glucose data transmission.
Based on these findings, we have implemented improvements to material
stability, antenna design, and firmware performance. A new batch of devices is
expected to be ready for implantation in dogs in December.
Preparations for our first-in-human trial (FIH) are progressing. While
regulatory approval was initially expected in Q3 2025, the evaluation process
has taken longer than anticipated. At the end of October, the Norwegian
Medical Products Agency (NoMA) validated our application, confirming that the
documentation is complete and compliant. Final approval may be granted by
mid-December 2025, allowing study initiation in Q1 2026. This pilot study will
provide essential clinical validation ahead of the pivotal CE-marking trial in
2026, paving the way for a commercial launch in Europe in 2027.
Our team remains focused, disciplined, and dedicated to achieving Lifecare's
next major milestone - bringing our novel CGM technology from development to
clinical trials for diabetes patients, while creating lasting value for our
shareholders.
Q3 2025 results presentation:
CEO Joacim Holter and CFO Renete Kaarvik will present live on webcast today at
10:00 a.m. CET.
To access the webcast Join the meeting here.
(https://eur04.safelinks.protection.outlook.com/ap/t-59584e83/?url=https%3A%2F%2Fteams.microsoft.com%2Fl%2Fmeetup-join%2F19%253ameeting_MjhiMDliMmUtZmU3YS00MmQ3LWFmZjAtMjFkYTM2ODA4NzJi%2540thread.v2%2F0%3Fcontext%3D%257b%2522Tid%2522%253a%252210b30f00-1bbd-4041-9c4d-64749f4a7041%2522%252c%2522Oid%2522%253a%25223758e62c-12e5-4419-a645-4b77ef5225be%2522%257d&data=05|02|asle.wingsternes%40lifecare.no|02ab5775069c4453b5b308de187b70da|c5fbb1c64eb045db9f3c6e20ebcd710e|0|0|638975115642037858|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=H%2B69p81%2FuJ%2FRcOUfC%2FO9leLDEu9GxppO%2FQ7q47qgW6M%3D&reserved=0)
A recording of the webcast will be available on our website after the event.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information has been submitted pursuant to the Securities Trading Act ยง
5-12 and MAR Article 17. The information was submitted for publication at
2025-11-12 07:00 CET.